The nanofiber morphology and multivalent presentation of IAVPTGVA and LTFPGSAED peptides as DPP-IV and ACE inhibitors in vitro on Caco-2 human intestinal cells could offer a future targeting strategy for the prevention of metabolic syndrome through their consumption as edible nanonutraceuticals. Here, FAP is linked to metabolic syndrome.